An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

UCI-17-31
NCT03144687
Cancer - Myeloid and Monocytic Leukemia
Angela G Fleischman
Open
Treatment
INC424, Itacitinib, Ruxolitinib
II
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.